Caribou Biosciences (CRBU) IPO Opens 10% Higher

Today's IPO for Caribou Biosciences, Inc. (NASDAQ: CRBU) opened for trading at $17.65 after pricing 19,000,000 shares of common stock at a public offering price of $16.00 per share.

BofA Securities, Citigroup, and SVB Leerink are acting as joint book-running managers for this offering.

Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company’s proprietary chRDNA technology toward the development of next-generation, genome-edited allogeneic immune cell therapies. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. The therapies target cell surface antigens for which autologous CAR-T cell therapeutics have previously demonstrated clinical proof-of-concept as well as additional emerging targets.

You May Also Be Interested In

• Longeveron names Nirav Jhaveri as CFO
• K Wave Media prices $1M registered direct offering at $1.90 per share
• Non-Invasive Monitoring Systems files to offer 8.1M shares